title: Gene-expression Profiling in Patients with Plasma Cell Myeloma Treated with Novel Agents.
abstract: OBJECTIVE
  Novel agents such as thalidomide, lenalidomide and bortezomib have in part anti-angiogenic properties. In this study, we examined gene expression of angiogenic molecules in patients with plasma cell myeloma (PCM).
  
  
  METHODS
  We included 93 patients with PCM treated with novel agents (immunomodulatory drugs (IMiDs), bortezomib or a combination of both). The mRNA levels of angiogenic molecules were measured using the Human Angiogenesis RT2 Profiler PCR Array. The response evaluation was performed after three cycles.
  
  
  RESULTS
  Regarding all 93 patients, gene expression of 15 out of 84 genes tested (pre- and post-treatment and changes in levels pre-treatment/post-treatment) were significantly different in responders compared to non-responders. Responders had a lower expression of pro-angiogenic factors and increased expression of antiangiogenic factors.
  
  
  CONCLUSIONS
  In the IMiD-treated groups we found significant changes of expression of angiogenic genes in responders compared to non-responders, whereas in the bortezomib-based group the difference in expression of angiogenic genes was not significant.
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland Division of Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland medingerm@uhbs.ch.
authors.forename: Michael
authors.initials: M
authors.lastname: Medinger
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Jörg
authors.initials: J
authors.lastname: Halter
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Dominik
authors.initials: D
authors.lastname: Heim
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Andreas
authors.initials: A
authors.lastname: Buser
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Sabine
authors.initials: S
authors.lastname: Gerull
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Claudia
authors.initials: C
authors.lastname: Lengerke
authors.affiliation: Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Jakob
authors.initials: J
authors.lastname: Passweg
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000235:genetics; D059467:Transcriptome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents
keywords: Angiogenesis; bortezomib; gene expression; immunomodulatory drugs; plasma cell myeloma